Cancer Family
Mast Cell Neoplasm
CI-CAN-00000257Explore in graph →
HematologicNon-malignant9 active trials2 approved drugs4 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000257Explore in graph →
Clinical trials
101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06432556 | Study of Cellular Heterogeneity in Patients With Mastocytosis(MastCellHet) | unknown | N/A | 26 | University Hospital, ToulouseOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04655118 | Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis | unknown | Phase 2 | 121 | Telios Pharma, Inc.INDUSTRY | 13 | May 10, 2024 | clinicaltrials |
| NCT05504408 | Observational Study for the Evaluation of Incidence of Systemic Mastocytosis in t(8;21) Acute Myeloid Leukemia | unknown | — | 200 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT06013683 | A Registry for Patients With Systemic Mastocytosis in China | unknown | — | 150 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05923372 | Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis(DALY-MAST) | unknown | — | 160 | University Hospital, ToulouseOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT04333108 | Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | unknown | Phase 3 | 140 | AB ScienceINDUSTRY | 8 | May 6, 2023 | clinicaltrials |
| NCT05084872 | Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients(HCQMa) | unknown | Phase 2 / Phase 3 | 30 | University Hospital, ToulouseOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT04615663 | Assessment of Burden Disease in Patients With Mast Cell Disorders(MCD&BuDi) | unknown | — | 200 | University Hospital, ToulouseOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT04377828 | Improvement of Pigmented Skin Lesions in Patients With Mastocytosis After Performing 2 Sessions of Pigment Laser(LaserMasto) | unknown | N/A | 34 | University Hospital, ToulouseOTHER | 1 | Sep 25, 2020 | clinicaltrials |
| NCT03340155 | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases(BioUV2017) | unknown | N/A | 240 | Medical University of GrazOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01602939 | Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis | unknown | Phase 2 / Phase 3 | 10 | Hospital Virgen de la SaludOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01920204 | Midostaurin in Indolent Systemic Mastocytosis | unknown | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jan 19, 2015 | clinicaltrials |
| NCT00979160 | Evaluation of Response of Dasatinib to Treat Mastocytosis | unknown | Phase 2 | 30 | Federico II UniversityOTHER | 1 | Sep 18, 2009 | clinicaltrials |
Data updated 22 days agoSource updated May 29, 2024source: clinicaltrials